Hauj lwm lawm

Kev tsis

Taw qhia

Tirzepatide2

Factory 2

musclepic 1

Khoom Description

1. Txheej txheem cej luam ntawm cov tshuaj thiab cov yam ntxwv ntawm Tirzepatide

1. Molecular Nature thiab Chemical Composition

Tirzepatide yog ib qho hluavtaws linear peptide tsim los ntawm 39 amino acids, nrog rau nws ib nrab - lub neej txuas ntxiv los ntawm kev hloov pauv ntawm fatty acid sab saw. Nws cov qauv tshuaj sib xyaw ua ke cov yam ntxwv ntawm ob qho tib si ntuj peptides thiab complex hloov peptides, nthuav tawm ob qho kev ua haujlwm lom neeg zoo thiab muaj zog ruaj khov. Nws cov mis molecular feem ntau yog siab tshaj C200, nrog rau qhov hnyav molecular tshaj 4800 Da, faib nws raws li nruab nrab - mus rau - ntev molecular hnyav "ntev peptide" tshuaj.

2. Cov qauv tsim qauv

Tirzepatide ntiav "dual{0}}lub hom phiaj tsim": ib feem ntawm cov kab ke ua raws li qhov chaw nquag ntawm GLP-1, thaum lwm qhov yog homologous rau GLP-1 agonist sequence. Kev ua kom zoo dua qub thiab hloov pauv amino acid txhim kho receptor selectivity.

Nyob rau tib lub sijhawm, nws cov saw hlau sab yog txuas mus rau qhov sib txuas ntawm C20 fatty acid, ua kom nws khi rau albumin thiab ua tiav ntev - ua cov tshuaj pharmacokinetic nrog kev txhaj tshuaj txhua lub lim tiam.

3. Daim ntawv lub cev thiab xim

Raw Material Powder Qib Tirzepatide feem ntau yog:

Dawb kom tawm -dawb lyophilized hmoov

Uniform kev ntxhib los mos, zoo hais

Tsis muaj ntxhiab tsw

Cov dej zoo solubility, dissolves sai sai rau hauv cov kua ntshiab los yog me ntsis cloudy kua

Cov xim daj daj lossis xim grey feem ntau qhia tau hais tias kev cia khoom lossis oxidation thiab feem ntau tsis ua raws li cov qauv siab - zoo.

2. Paub meej Physicochemical Properties

1. Cov khoom siv hmoov

Cov tsos mob: Dawb los yog tawm -dawb lyophilized hmoov

Kev ruaj ntseg: Kev ruaj ntseg siab nyob rau hauv qis - kub kom qhuav

Solubility: Yooj yim soluble hauv dej rau kev txhaj tshuaj thiab tsis daws teeb meem

Impurity Control: Cov impurities (peptide truncation, oxidation khoom) yuav tsum tsis tshua muaj tsawg nyob rau hauv siab - formulations zoo.

2. Isoelectric Point thiab pH yam ntxwv

Vim hais tias Tirzepatide muaj ntau yam hydrophilic thiab hydrophobic amino acids, nws cov tshuaj yog qhov ruaj khov nyob rau hauv ib tug pH ntau ntawm 4.5-7.5, ua rau nws haum raws li ib tug tsis pH ntau yam rau txhaj tshuaj.

3. Cov yam ntxwv ruaj khov

Tirzepatide yog rhiab heev rau kub thiab av noo thiab yuav tsum tau tub yees:

Qhov ntsuas kub zoo tshaj plaws: 2-8 ° C

Zam lub teeb thiab rov khov dua -thaw cycles.

Nws nthuav tawm qee qhov kev ruaj ntseg hauv cov tshuaj tsis muaj menyuam, tab sis kev cia ntev ntev tseem yuav ua rau peptide saw hydrolysis lossis oxidation.

3. Mechanism of Action: A Revolutionary Breakthrough in Dual Receptor Activation

Tirzepatide tus yam ntxwv tseem ceeb tshaj plaws ntawm cov tshuaj pharmacological yog kev ua haujlwm ib txhij ntawm ob qho tib si GIP thiab GLP-1 receptors, uas ua si sib txawv tab sis ua tiav lub luag haujlwm hauv vivo.

1. Cov teebmeem ntawm GIP receptor activation:

Txhim kho insulin secretion (glucose{0}}dependent)

Txhim kho lipid metabolism

Txhim kho cov tshuaj insulin rhiab heev

Txhim kho lub cev ua cov as-ham

2. Cov teebmeem ntawm GLP-1 receptor activation:

Txhawb kev tsim cov tshuaj insulin

Inhibits glucagon secretion

Delays plab hnyuv

Txo qab los noj mov thiab nce satiety

Txhawb kev tswj qhov hnyav

3. Synergistic cov teebmeem ntawm kev ua haujlwm dual:

Cov kev tshawb fawb qhia tau hais tias kev sib xyaw ua ke ntawm ob qho tib si tsim cov kev txhim kho metabolic zoo dua rau ib leeg GLP-1 agonists, suav nrog:

Cov piam thaj ntau dua - txo qis

Tseem ceeb dua qhov poob phaus

Ntau qhov glycemic ruaj khov

4. Kev kho mob zoo thiab xav tau tus nqi

1. Cov txiaj ntsig zoo hauv kev kho mob ntshav qab zib hom 2: Hauv kev sim tshuaj loj, Tirzepatide tau pom muaj cov piam thaj muaj zog- txo qis piv rau cov tshuaj tswj, nrog HbA1c txo qis tshaj 2.5%, deb tshaj cov tshuaj GLP-1 monotherapy.

2. Kev ua tau zoo hauv kev poob phaus

Ua tsaug rau nws cov txheej txheem agonist dual, Tirzepatide nthuav tawm qhov muaj peev xwm poob phaus, nrog qee qhov kev sim qhia qhov hnyav ntawm 15% -22%, nce los yog dhau qhov cuam tshuam ntawm qee qhov kev phais metabolic.

3. Qhov zoo ntawm Lub Limtiam Ntev -Kev Ua Haujlwm Zoo

Nws fatty acid side chains ncua nws nyob rau hauv vivo ib nrab -lub neej, muab ib tug yooj yim dosing txoj kev thiab ho txhim kho adherence.

4. Kev txhim kho ntawm metabolic Syndrome

Xws li:

Txo cov ntshav qabzib sai

Txhim kho insulin tsis kam

Txhim kho lipid metabolism (txo triglycerides, thiab lwm yam)

Cov txiaj ntsig zoo rau cov cim inflammatory

5. Kev tsim khoom thiab tsim cov yam ntxwv (Tsis yog-Cov kauj ruam sib xyaw, kev nyab xeeb saib xyuas)

Raws li cov tshuaj peptide, Tirzepatide feem ntau yog npaj siv cov khoom siv -theem peptide synthesis (SPPS) technology. Txawm li cas los xij, cov khoom siv raw khoom yuav tsum tau ua raws li nram qab no:

Amino acid sequence sib dhos

Side chain modification

Purification (HPLC)

Lyophilization ntawm cov khoom tiav

Thaum kawg, nws yog tsim los rau hauv cov hmoov siv rau hauv kev txhaj tshuaj lossis ua ntej - puv syringes.

Kab lus no tsis hais txog kev sim cov txheej txheem hluavtaws, tab sis tsuas yog piav qhia txog nws txoj kev tsim khoom thiab kev tsim qauv.

6. Kev soj ntsuam zoo thiab kuaj cov qauv

Siab -Kev kuaj Tirzepatide zoo suav nrog:

Kev tshuaj ntsuam xyuas (dawb lyophilized hmoov)

Peptide purity (feem ntau siab dua 98%)

Kev tsom xam impurity (truncated peptides, oxidized peptides, thiab lwm yam)

Cov dej noo

pH compatibility

Kev txheeb xyuas qhov zoo (MS, HPLC, NMR)

High- cov khoom purity yuav tsum pom tsuas yog ob peb impurity peaks hauv HPLC chromatogram.

7. Kev ntim khoom thiab khaws cia

Txhawm rau kom peptide chain stability, raw khoom qib Tirzepatide yuav tsum tau ceev cia:

Lub tub yees 2-8 degree

Ntim ntim

Tsis txhob ya raws

Tsis txhob raug lub teeb

Dissolve nrog dej tsis muaj menyuam rau kev txhaj tshuaj ua ntej txhaj tshuaj

Lyophilization ho txhim kho nws lub sijhawm ntev - muaj peev xwm khaws cia.

8. Cov ntsiab lus

Raws li lub tswv yim tshiab dual - receptor agonist peptide tshuaj, Tirzepatide qhov zoo yog tsis yog nyob rau hauv nws cov qauv tsim xwb tab sis kuj nyob rau hauv nws cov kev txhim kho metabolic tseem ceeb thiab kev cia siab rau daim ntawv thov kev kho mob. Los ntawm nws cov khoom siv physicochemical thiab cov tsos mob rau nws qhov kev ua tau zoo thiab cov tshuaj pharmacokinetics, Tirzepatide qhia tau tias muaj txiaj ntsig zoo heev thiab kev lag luam muaj peev xwm.

Nws tshwm sim sawv cev rau lub kiv puag ncig hauv kev kho mob metabolic, muab lub zog ntau dua, ua tiav, thiab cog lus kho cov tswv yim rau cov kab mob metabolic nyuaj xws li ntshav qab zib thiab rog.